Skip to content

Call Us Today: 812-689-0791

info@neuraxis.com

812-689-0791

info@neuraxis.com

NeurAxis
NeurAxis
  • Home
  • Products
    • IB-Stim
    • RED
  • About
    • About NeurAxis
    • Our Team
    • Patents
  • Investor Relations
  • Contact
  • Home
  • Products
    • IB-Stim
    • RED
  • About
    • About NeurAxis
    • Our Team
    • Patents
  • Investor Relations
  • Contact

PENFS

35 items

  • Press Release

    May 5, 2025

    NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025

    Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern Time

    Continue reading
  • Press Release

    April 15, 2025

    NeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1×1 Meetings on Thursday, April 24, 2025

    NeurAxis, Inc., to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025

    Continue reading
  • Press Release

    March 20, 2025

    NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues

    NeurAxis, Inc., today announced results for the fourth quarter and fiscal year 2024 for the period ended December 31, 2024.

    Continue reading
  • Press Release

    March 12, 2025

    NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025

    CARMEL, Ind., March 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE

    Continue reading
  • Press Release

    January 21, 2025

    NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States

    CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE

    Continue reading
  • Press Release

    January 13, 2025

    NeurAxis Inc. Issues Letter to Shareholders

    CARMEL, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE

    Continue reading
  • Press Release

    January 8, 2025

    NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year

    Revenues in 4Q24 increased approximately 50% versus 4Q23 Cash balance as of 12/31/24 was approximately

    Continue reading
  • Press Release

    January 6, 2025

    NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

    CARMEL, Ind., Jan. 06, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE

    Continue reading
  • Press Release

    December 10, 2024

    NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation

    RED has been designed to duplicate test performance of traditional balloon expulsion test (BET) and

    Continue reading
  • Press Release

    November 12, 2024

    NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues

    Conference call will be held today, Tuesday, November 12 at 9:00 am ET CARMEL, Ind.,

    Continue reading
12Next
NeurAxis
(812) 689-0791
info@neuraxis.com

Quick Links

  • Home
  • IB-Stim
  • RED
  • Investor Relations
  • Home
  • IB-Stim
  • RED
  • Investor Relations

About NeurAxis

  • About
  • Our Team
  • Patents
  • Contact Us
  • About
  • Our Team
  • Patents
  • Contact Us

Sign up for News

© 2025 NeurAxis, Inc.  |  All Rights Reserved  |  Privacy & Terms
© 2025 NeurAxis, Inc.  |  All Rights Reserved  |  Privacy & Terms
Page load link
Go to Top